Fourth-quarter and full-year 2025 results | Adjusted diluted EPS | | | | --- | --- | --- | | Fourth quarter | $1.501 | ↑12% | | Full year | $5.152 | % ↑10 | | W orldwide sales | Organic* sales growth for underlying base business** | 5 Full-year 2026 guidance | | $11.5B | ↑3.8%3 | 6.5% to 7.5% | | Fourth quarter | | Organic sales growth | | $44.3B | ↑6.7%4 | $5.55 to $5.80 | | Full year | | Adjusted diluted EPS | Key business units | Fourth-quarter sales Expanding in the fast-growing pulsed field ablation (P ...

Core Insights - Abbott reported strong financial results for Q4 2025, with total worldwide sales reaching $11.459 billion, a 4.4% increase from Q4 2024 [28] - The company achieved double-digit earnings per share growth, with adjusted diluted EPS of $1.50, reflecting a 12% increase [5] - Abbott's full-year 2025 sales totaled $44.328 billion, marking a 5.7% increase compared to 2024 [28] Financial Performance - Q4 2025 sales increased 4.4% on a reported basis and 3.0% on an organic basis, with a 3.8% increase when excluding COVID-19 testing-related sales [5][28] - Full-year 2025 GAAP diluted EPS was $3.72, while adjusted diluted EPS was $5.15, reflecting a 10% growth [5][28] - Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80 [5][22] Segment Performance - In Q4 2025, Nutrition sales decreased by 8.9% on a reported basis and 9.1% on an organic basis, primarily due to lower sales volumes [9][10] - Diagnostics sales in Q4 2025 were $2.457 billion, a decrease of 2.5% on a reported basis and 3.6% on an organic basis [12][28] - Medical Devices sales increased by 12.3% on a reported basis and 10.4% on an organic basis, driven by strong growth in Electrophysiology and Diabetes Care [19][20] Strategic Developments - Abbott announced an agreement to acquire Exact Sciences, positioning the company to enter the cancer diagnostics market [5] - The company received FDA approval for its Volt™ PFA System and CE Mark for its TactiFlex™ Duo Ablation Catheter, enhancing its Electrophysiology portfolio [5][10] Dividend Information - Abbott declared a quarterly dividend of $0.63 per share, marking the 408th consecutive quarterly dividend and reflecting a commitment to returning value to shareholders [24]

Core Insights - QuidelOrtho Corporation emphasizes the importance of consistent donor engagement to address pressures on the blood supply [1][2] - The podcast discusses how evolving clinical practices, climate disruptions, and persistent demand shape the modern blood supply [2] Industry Context - Everyday emergencies and climate-driven events create unpredictable demand for blood products, impacting supply [5] - The growth of prehospital low-titer whole blood programs increases the consumption of O-type units, necessitating targeted donor recruitment and precise inventory management [5] - Automation through standardized, high-throughput immunohematology platforms enhances safety and operational continuity during demand surges [5] - Every blood type is crucial for supporting transfusion needs and the diagnostic reagents necessary for safe transfusions [5] Company Overview - QuidelOrtho Corporation is a leading global provider of diagnostic solutions, focusing on advancing fast, accurate, and reliable results to improve patient outcomes [4] - The company collaborates with healthcare providers to enhance diagnostics that connect insights with solutions, facilitating informed decisions and better care [4]

As filed with the U.S. Securities and Exchange Commission on January 21, 2026 Registration No. 333-292125 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 20/20 BIOLABS, INC. (Exact name of registrant as specified in its charter) Delaware 8734 57-2272107 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 15810 Gaither Road, Suite 235 Gaithersburg, MD 20877 ...

Core Viewpoint - QuidelOrtho Corporation will report its financial results for Q4 and full year 2025 on February 11, 2026, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call starting at 2:00 p.m. PT / 5:00 p.m. ET [2] - Interested parties can access the call via the Company's website or by phone using specific dial-in numbers [2] Conference Call Replay - A replay of the conference call will be available shortly after the event on the Company's website [3] Company Overview - QuidelOrtho Corporation is a leading global provider of diagnostic solutions, focusing on advancing fast, accurate, and reliable results to improve patient outcomes [4] - The company has expertise in clinical chemistry, immunoassay, immunohematology, and molecular testing [4]

Core Viewpoint - Qiagen is considering strategic options, including a potential sale of the diagnostics firm due to renewed takeover interest [1] Group 1 - Qiagen is reportedly exploring various strategic options [1] - The company is experiencing fresh interest from potential buyers [1]

Core Insights - Interpace Biosciences reported preliminary 2025 thyroid testing revenue growth of 21% compared to the previous year, with total revenue estimated at approximately $38-39 million, of which $34-35 million is attributed to thyroid testing [3][4] - The company has initiated guidance for 2026, projecting a revenue of approximately $40 million, representing a 16% growth in thyroid testing revenue over 2025 [4] - All preferred stock has been converted to common stock, simplifying the capital structure and resulting in approximately 27.7 million shares outstanding [5][6] - Interpace has a debt-free balance sheet and is operating with positive net income and EBITDA [7] - The company plans to seek an uplisting on the Nasdaq Stock Market in 2026, aiming to attract more investors and facilitate growth [7][8] Revenue Performance - Preliminary 2025 revenue from continuing operations is approximately $38-39 million, with thyroid testing contributing around $34-35 million [3] - The growth in thyroid testing revenue is approximately 21% over 2024 [3] - For 2026, the company anticipates revenue of about $40 million, with 100% derived from thyroid testing, indicating a projected growth of 16% [4] Capital Structure - In October 2024, all Series C Preferred shares were converted into common stock, resulting in the issuance of approximately 23,267,327 shares [5] - Following the conversion, the total pro forma basic shares outstanding is approximately 27.7 million [6] - Major shareholders include 1315 Capital with approximately 34% and Ampersand with about 50% of the outstanding common stock [6] Strategic Plans - The conversion of preferred stock and the elimination of debt are seen as pivotal milestones in the company's capital structure [7] - The company aims to leverage its simplified capital structure to focus on scaling its profitable thyroid diagnostics business [7] - Plans for uplisting to the Nasdaq are intended to enhance investor participation and support growth initiatives in sales and research [8]

Market Overview - The US equity market ended Q4 2025 positively, with the S&P 500 increasing by 2.7%, reflecting steady upward momentum [1] - Investor optimism was bolstered by better-than-expected corporate earnings, the US Federal Reserve's interest rate easing stance, and a resilient macroeconomic backdrop [1] - Clarity on trade policy provided additional support, although there was increasing divergence below the index level [1] Investment Trends - There is growing skepticism regarding AI investments due to bottlenecks, financing challenges, and uncertainty about return generation [1] - The firm continues to identify secular trends that present attractive investment opportunities for small-cap stocks [1] Fund Performance - In Q4 2025, Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index [1] - The Utilities and Financials sectors contributed positively to the Fund's performance, while the Consumer Discretionary and Information Technology sectors detracted from it [1] Company Spotlight: Natera, Inc. - Natera, Inc. (NASDAQ:NTRA) is highlighted as a leading diagnostics and research company specializing in molecular testing services [2][3] - The stock had a one-month return of -0.31% but gained 46.03% over the last 52 weeks, closing at $231.25 per share with a market capitalization of $32.248 billion on January 16, 2026 [2] - Natera provides high-value genetic testing across reproductive health, oncology, and transplant, utilizing a proprietary cell-free DNA liquid biopsy platform [3] - The company reported strong fiscal Q3 earnings, with management indicating revenue and margin performance exceeding expectations due to higher test volumes and favorable reimbursement dynamics, particularly in the Signatera franchise [3]

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ended the fourth quarter on a strong note, with the S&P surging 2.7%, maintaining its steady upward momentum. Investors' optimism was supported by better-than-expected corporate earnings, the US Federal Reserve’s further interest rate easing stance, and a resilient macroeconomic backdrop. Improving clarity on ...

Core Insights - The Alger Small Cap Focus Fund's fourth-quarter 2025 investor letter indicates a strong performance in the US equity market, with the S&P 500 rising by 2.7% due to better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The letter highlights a divergence in market performance, particularly regarding AI investments, which face skepticism due to various challenges [1] - The Fund's Class A shares outperformed the Russell 2000 Growth Index, with contributions from the Utilities and Financials sectors, while Consumer Discretionary and Information Technology sectors negatively impacted performance [1] Company Insights - Exact Sciences Corporation (NASDAQ:EXAS) is noted for its cancer screening and diagnostic products, with a market capitalization of $19.453 billion [2] - The stock of Exact Sciences Corporation closed at $102.43 per share on January 16, 2026, with a one-month return of 0.60% and a remarkable 97.97% increase over the past 52 weeks [2] - The company is recognized for its Cologuard noninvasive colorectal cancer screening and has a pipeline that includes molecular residual disease (MRD) and multi-cancer early detection (MCED) testing [3] - Exact Sciences' stock saw positive contributions during the quarter following Abbott's announcement of a definitive all-cash acquisition agreement valued at approximately $21 billion, which provided a significant premium and drove the stock price higher [3]